Vaccines Based on Dendritic Cells: Breaking Barriers to New Immune Response Approach
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 20 February 2025 | Viewed by 237
Special Issue Editor
Interests: food; nutrients; immunology; innate and adaptative response; immunometabolism; signaling pathways; flow cytometry; cell culture; allergy; allergic rhinitis; chronic rhinosinusitis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Dendritic cells (DCs) are versatile cells that bridge the gap between innate and adaptive immune responses. They are potent antigen-presenting cells that control both T cell immunity and tolerance. DCs are often downregulated in diseases such as cancer, where they are called tolerogenic DCs and have a crucial role in inducing peripheral tolerance. As a result, DCs have been successfully targeted using inhibitory drugs or DC-based vaccines as immunotherapies. These therapies are often employed as a second-line treatment after traditional therapies prove ineffective. DC vaccines have a significant role in preventing relapses and metastasis post tumor treatment. Recent studies on vaccines based on nucleic acids such as DNA or mRNA have shown remarkable results in treating diseases such as COVID-19 and multiple solid tumors. We invite contributions of original reports, observations, or reviews to highlight (i) their role in preventing relapses in cancer, (ii) the metabolic signaling pathway target, (iii) the ability to cross the blood–brain barrier in pathological processes or as a vaccination strategy, and (iv) recent advances in novel therapeutic vaccines based on dendritic cells.
Prof. Dr. Soledad Lopez-Enriquez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- plasmacytoid dendritic cells
- myeloid dendritic cells
- immunotolerance
- regulatory T cells
- cytotoxic T cells
- NK cells
- immunotherapies
- nanovaccines
- immunometabolism
- delivery systems
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
